Cohance Lifesciences Limited (COHA)

Currency in INR
462.30
+2.85(+0.62%)
Closed·
COHANCE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
453.20465.65
52 wk Range
266.70587.00
Key Statistics
Bid/Ask
462.50 / 462.30
Prev. Close
459.45
Open
455
Day's Range
453.2-465.65
52 wk Range
266.7-587
Volume
318.95K
Average Volume (3m)
887.81K
1-Year Change
-21.551%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COHANCE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
510.50
Upside
+10.43%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Cohance Lifesciences Limited News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
1 Hold
4 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 510.50
(+10.43% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
ICICI Securities
Sell365.00-21.05%-DowngradeNov 09, 2026
JPMorgan
Hold440.00-4.82%490.00MaintainNov 09, 2026
Investec
Buy560.00+21.13%-New CoverageOct 20, 2026
ICICI Securities
Sell365.00-21.05%415.00MaintainAug 06, 2026
JPMorgan
Hold490.00+5.99%440.00MaintainAug 06, 2026

Cohance Lifesciences Limited Earnings Call Summary for Q1/2027

  • Q1 FY2027 revenue fell 23% YoY to $4.22B, missing estimates by $197M; adjusted EBITDA margin compressed to 2.2% in weakest quarter ever.
  • NJ Bio losses dragged consolidated profitability while Sapala oligonucleotides surged 2.5x YoY; API Plus remained resilient despite margin pressure.
  • Management guided Q1 as year's low point, expects sequential Q2 improvement and YoY growth resuming in second half of fiscal 2027.
  • Pharma CDMO pipeline strengthening with two molecules entering commercial supply; seven new API Plus filings planned for FY2027.
  • Stock rose 1.1% to $429.45 as investors looked past weak results; shares remain 59% below 52-week high amid execution and funding risks.
Last Updated: 2026-08-05, 10:46 a/m
Read Full Transcript

Earnings

Latest Release
Nov 06, 2026
EPS / Forecast
0.40 / 0.05
Revenue / Forecast
4.77B / 4.78B
EPS Revisions
Last 90 days

COHANCE Income Statement

Compare COHANCE to Peers and Sector

Metrics to compare
COHANCE
Peers
Sector
Relationship
P/E Ratio
373.4x50.0x−0.2x
PEG Ratio
−4.550.790.00
Price/Book
4.5x4.0x2.6x
Price / LTM Sales
8.6x6.5x2.6x
Upside (Analyst Target)
10.4%16.2%77.0%
Fair Value Upside
Unlock4.4%13.7%Unlock

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Employees
1212
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
82.79M21.64%38.27B
Other Institutional Investors
336.99M78.36%155.79B
Public Companies & Retail Investors
0.000.00%0.00
Total
419.78M100.00%194.06B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Berhyanda Midco Limited33.34%127,539,59258,961,553
Advent International GPE IX, L.P.24.15%92,390,57842,712,164

People Also Watch

1,515.60
SYRM
-0.09%
4,215.00
DATP
+2.48%
819.50
WHIR
-1.30%
1,531.60
GESC
-1.51%
3,331.90
GLAD
+1.18%

FAQ

What Is the Cohance Lifesciences (COHANCE) Stock Price Today?

The Cohance Lifesciences stock price today is 462.30 INR.

What Stock Exchange Does Cohance Lifesciences Trade On?

Cohance Lifesciences is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Cohance Lifesciences?

The stock symbol for Cohance Lifesciences is "COHANCE."

What Is the Cohance Lifesciences Market Cap?

As of today, Cohance Lifesciences market cap is 176.87B INR.

What Is Cohance Lifesciences's Earnings Per Share (TTM)?

The Cohance Lifesciences EPS (TTM) is 1.23.

When Is the Next Cohance Lifesciences Earnings Date?

Cohance Lifesciences will release its next earnings report on Feb 08, 2027.

From a Technical Analysis Perspective, Is COHANCE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cohance Lifesciences Stock Split?

Cohance Lifesciences has split 1 times.

How Many Employees Does Cohance Lifesciences Have?

Cohance Lifesciences has 1212 employees.

What is the current trading status of Cohance Lifesciences (COHANCE)?

As of Nov 22, 2026, Cohance Lifesciences (COHANCE) is trading at a price of 462.30 INR, with a previous close of 459.45 INR. The stock has fluctuated within a day range of 453.20 INR to 465.65 INR, while its 52-week range spans from 266.70 INR to 587.00 INR.

What Is Cohance Lifesciences (COHANCE) Price Target According to Analysts?

The average 12-month price target for Cohance Lifesciences is 510.50 INR, with a high estimate of 1150 INR and a low estimate of 280 INR. 5 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +10.43% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.